Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Aug 5:15:82.
doi: 10.1186/s13020-020-00359-1. eCollection 2020.

Traditional Chinese medicine for anti-Alzheimer's disease: berberine and evodiamine from Evodia rutaecarpa

Zhiling Fang  1 , Yuqing Tang  1 , Jiaming Ying  1 , Chunlan Tang  1 , Qinwen Wang  1
Affiliations
Review

Traditional Chinese medicine for anti-Alzheimer's disease: berberine and evodiamine from Evodia rutaecarpa

Zhiling Fang et al. Chin Med. .

Abstract

Alzheimer's disease (AD) is one of the most common diseases in elderly people with a high incidence of dementia at approximately 60-80%. The pathogenesis of AD was quite complicated and currently there is no unified conclusion in the academic community, so no efficiently clinical treatment is available. In recent years, with the development of traditional Chinese medicine (TCM), researchers have proposed the idea of relying on TCM to prevent and treat AD based on the characteristic of multiple targets of TCM. This study reviewed the pathological hypothesis of AD and the potential biomarkers found in the current researches. And the potential targets of berberine and evodiamine from Evodia rutaecarpa in AD were summarized and further analyzed. A compound-targets-pathway network was carried out to clarify the mechanism of action of berberine and evodiamine for AD. Furthermore, the limitations of current researches on the TCM and AD were discussed. It is hoped that this review will provide some references for development of TCM in the prevention and treatment of AD.

Keywords: Alzheimer’s disease; Berberine; Evodiamine; Pathogenic hypothesis; Traditional Chinese medicine.

PubMed Disclaimer

Conflict of interest statement

Competing interestsThe authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
The main pathogenesis of Alzheimer’s disease
Fig. 2
Fig. 2
The structures of BBR and Evo
Fig. 3
Fig. 3
The pharmacodynamic mechanism of Evo for Alzheimer’s disease
Fig. 4
Fig. 4
The pharmacodynamic mechanism of BBR for Alzheimer’s disease
Fig. 5
Fig. 5
Compound-target-pathways network of BBR and Evo for Alzheimer’s disease
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Brooks LRK, Mias GI. Data-driven analysis of age, sex, and tissue effects on gene expression variability in Alzheimer’s disease. Front Neurosci. 2019;13:392. - PMC - PubMed
    1. Alzheimer’s A. 2016 Alzheimer’s disease facts and figures. Alzheimer’s Dementia J the Alzheimer’s Assoc. 2016;12:459–509. - PubMed
    1. Feng L, Liao YT, He JC, Xie CL, Chen SY, Fan HH, Su ZP, Wang Z. Plasma long non-coding RNA BACE1 as a novel biomarker for diagnosis of Alzheimer disease. BMC Neurol. 2018;18:4. - PMC - PubMed
    1. Blackburn J, Zheng Q, Grabowski DC, Hirth R, Intrator O, Stevenson DG, Banaszak-Holl J. Nursing home Chain affiliation and its impact on specialty service designation for Alzheimer disease. Inquiry J Med Care Org Provis Fin. 2018;55:46958018787992. - PMC - PubMed
    1. Atri A. Current and future treatments in Alzheimer’s disease. Semin Neurol. 2019;39:227–240. - PubMed

LinkOut - more resources